Loading
Ziv-aflibercept (Zaltrap) is a decoy receptor that soaks up the blood-vessel growth signal VEGF. It is added to the FOLFIRI chemotherapy combination for bowel cancer that has spread and progressed after oxaliplatin.
Ziv-aflibercept was approved by the FDA in August 2012 with FOLFIRI for metastatic colorectal cancer resistant to or progressing after an oxaliplatin-containing regimen, on the VELOUR trial (1,226 patients) in which adding the drug modestly improved overall survival and progression-free survival over FOLFIRI plus placebo, including in patients who had received bevacizumab. The EU authorised Zaltrap in 2013. Its role overlaps with bevacizumab continued beyond progression and with ramucirumab (RAISE), and cost has limited uptake. Haemorrhage, gastrointestinal perforation and compromised wound healing carry boxed warnings; hypertension and proteinuria are common. The same molecule is the ophthalmic drug Eylea.
Fusion of VEGFR1 and VEGFR2 extracellular domains with human IgG1 Fc; binds VEGF-A, VEGF-B and placental growth factor with sub-picomolar affinity, preventing receptor activation and angiogenesis. Connects to VEGF / VEGFR.
1.Ziv-aflibercept binds VEGF / VEGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2012 | Metastatic colorectal cancer resistant to or progressing after oxaliplatin, with FOLFIRI |
| EU | 2013 | Metastatic colorectal cancer resistant to or progressing after oxaliplatin, with FOLFIRI |
| US | 2012 | Metastatic colorectal cancer resistant to or progressing after an oxaliplatin-containing regimen, with FOLFIRI · Approved August 2012 on VELOUR. |
| EU | 2013 | Metastatic colorectal cancer resistant to or progressing after an oxaliplatin-containing regimen, with FOLFIRI · Zaltrap marketing authorisation issued 1 February 2013. |
| England (NICE) | 2014 | Not recommended · TA307, published 25 March 2014: aflibercept with irinotecan and fluorouracil-based therapy is not recommended within its marketing authorisation; patients already receiving it could continue. |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Ziv-aflibercept" OR ABSTRACT:"Ziv-aflibercept" OR TITLE:"Zaltrap" OR ABSTRACT:"Zaltrap" OR TITLE:"Aflibercept oncology formulation" OR ABSTRACT:"Aflibercept oncology formulation" OR TITLE:"VEGF Trap" OR ABSTRACT:"VEGF Trap") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ziv-aflibercept, not a curated reading list.
Shares VELOUR, Ramucirumab, FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR, Bevacizumab, Anti-angiogenic therapy.
Shares VEGF / VEGFR, Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), VEGF / VEGFR, Bevacizumab, Anti-angiogenic therapy.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.
Shares VEGF / VEGFR, Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Anti-angiogenic therapy, Colorectal cancer.